Violaine Planté-Bordeneuve

Violaine Planté-Bordeneuve

Auto-generated profile, based on publicly available information

Violaine Planté-Bordeneuve

Department of Neurology, Henri Mondor University Hospital, APHP, Créteil, France

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in Amyloid
Verified
Journal Article
Open access
DADavid Adams
David Adams
ITIvailo L. Tournev
Ivailo L. Tournev
MTMark S. Taylor
Mark S. Taylor
TCTeresa Coelho
Teresa Coelho
VPViolaine Planté-Bordeneuve
Violaine Planté-Bordeneuve
TCThe Helios-A Collaborators
The Helios-A Collaborators
The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients with hereditary transthyretin (ATTRv) amyloidosi...

16 December 2017 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
VPViolaine Plante-Bordeneuve
Violaine Plante-Bordeneuve

4 November 2020 in Amyloid
Verified
Journal Article
Closed access
FGFarida Gorram
Farida Gorram
MOMalin Olsson
Malin Olsson
FAFlora Alarcon
Flora Alarcon
GNGregory Nuel
Gregory Nuel
IAIntissar Anan
Intissar Anan
VPViolaine Planté-Bordeneuve
Violaine Planté-Bordeneuve
Hereditary transthyretin (ATTRv) amyloidosis is of autosomal dominant transmission, caused by a spectrum of mutations in the transthyretin (TTR) gene. The ATTRV30M (p.Val50Met) is the most frequent...

27 January 2024 in Expert Opinion on Drug Discovery
Verified
Journal Article
Open access
VPViolaine Planté-Bordeneuve
Violaine Planté-Bordeneuve
VPValentine Perrain
Valentine Perrain
Hereditary transthyretin (ATTRv) amyloidosis is a progressive, fatal disorder caused by mutations in the transthyretin (TTR) gene leading to deposition of the misfolded protein in amyloid fibrils. The main phenotypes are peripheral neuropathy (PN) and cardiomyopathy (CM). Gene silencing therapy, by dramatically reducing liver production of TTR, has transformed ATTRv-PN patient care in the last decade. In this drug discovery case history, the authors discuss the treatment history of ATTRv-PN and focus on the latest siRNA therapy: vutrisiran. Vutrisiran is chemically enhanced and N-acetylgalactosamin-conjugated, allowing increased stability and specific liver delivery. HELIOS-A, a phase III, multicenter randomized study, tested vutrisiran in ATTRv-PN and showed significant improvement in neuropathy impairment, disability, quality of life (QoL), gait speed, and nutritional status. Tolerance was acceptable, no safety signals were raised. Vutrisiran offers a new treatment option for patients with ATTRv-PN. Vutrisian's easier delivery and administration route, at a quarterly frequency, as well as the absence of premedication, are major improvements to reduce patients' disease burden and improve their QoL. Its place in the therapeutic strategy is to be determined, considering affordability.

10 September 2019 in Clinical Autonomic Research
Verified
Journal Article
Open access
PDF file
TGThierry Gendre
Thierry Gendre
VPViolaine Planté-Bordeneuve
Violaine Planté-Bordeneuve
Purpose: Hereditary transthyretin amyloidosis (hATTR) is a severe adult-onset progressive disease mainly involving the peripheral nervous system and the heart, with a prominent impact on the autonomic nervous system. This review summarizes the clinical aspects of autonomic dysfunction in hATTR, and their impact on quality of life as well as potential therapeutic options. Methods: Literature review. Results: Autonomic dysfunction, causing neurogenic orthostatic hypotension, gastroparesis, constipation, diarrhea, bladder dysfunction, and erectile dysfunction in males, has a major impact on the quality of life of patients with hATTR. Improvement of qualify of life in patients with hATTR implies periodic symptomatic screening and early management, taking into consideration comorbidities and medication side effects. The specific effect of the disease-modifying treatment on this aspect remains to be unraveled. Conclusions: Management of autonomic dysfunction in patients with hAATR is feasible and can result in improved qualify of life. Novel disease-modifying treatments for hAATR may contribute to improve autonomic dysfunction, although specific studies are required.

18 August 2023 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
TDThibaud Damy
Thibaud Damy
AZAmira Zaroui
Amira Zaroui
MTMarie de Tournemire
Marie de Tournemire
MKMounira Kharoubi
Mounira Kharoubi
RGRomain Gounot
Romain Gounot
ETEmmanuel Teiger
Emmanuel Teiger